“MUC1”的意思、由来-开放百科全书

Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene in humans.^[1] MUC1 is a glycoprotein with extensive O-linked glycosylation of its extracellular domain. Mucins line the apical surface of epithelial cells in the lungs, stomach, intestines, eyes and several other organs.^[2] Mucins protect the body from infection by pathogen binding to oligosaccharides in the extracellular domain, preventing the pathogen from reaching the cell surface.^[3] Overexpression of MUC1 is often associated with colon, breast, ovarian, lung and pancreatic cancers.^[4] Joyce Taylor-Papadimitriou identified and characterised the antigen during her work with breast and ovarian tumors.

Structure

MUC1 is a member of the mucin family and encodes a membrane bound, glycosylated phosphoprotein. MUC1 has a core protein mass of 120-225 kDa which increases to 250-500 kDa with glycosylation. It extends 200-500 nm beyond the surface of the cell.^[5]

The protein is anchored to the apical surface of many epithelia by a transmembrane domain. Beyond the transmembrane domain is a SEA domain that contains a cleavage site for release of the large extracellular domain. The release of mucins is performed by sheddases.^[6] The extracellular domain includes a 20 amino acid variable number tandem repeat (VNTR) domain, with the number of repeats varying from 20 to 120 in different individuals. These repeats are rich in serine, threonine and proline residues which permits heavy o-glycosylation.^[5]

Multiple alternatively spliced transcript variants that encode different isoforms of this gene have been reported, but the full-length nature of only some has been determined.^[7]

MUC1 is cleaved in the endoplasmic reticulum into two pieces, the cytoplasmic tail including the transmembrane domain and the extracellular domain. These domains tightly associate in a non-covalent fashion.^[8] This tight, non-covalent association is not broken by treatment with urea, low pH, high salt or boiling. Treatment with sodium dodecyl sulfate triggers dissociation of the subunits.^[9] The cytoplasmic tail of MUC1 is 72 amino acids long and contains several phosphorylation sites.^[10]

Function

The protein serves a protective function by binding to pathogens^[11] and also functions in a cell signaling capacity.^[10]

Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. e.g. The CanAg tumour antigen is a novel glycoform of MUC1.^[12] In the cell nucleus, the protein MUC1 regulates the activity of transcription factor complexes that have a documented role in tumor-induced changes of host immunity.^[13]

Diagnostic utility

In histopathology, the product of the MUC-1 gene is commonly referred to as epithelial membrane antigen or EMA. Using immunohistochemistry, it can be identified in a wide range of secretory epithelia and their neoplastic equivalents. It can also be used for the identification of mesenchymal tumours, such as synovial sarcoma and ovarian granulosa cell tumours.

Although other antibodies, such as cytokeratins, are more commonly used for the identification of metastatic carcinoma deposits, EMA can be used to distinguish mesothelioma, in which it is restricted to the cell membranes and associated micovilli, from adenocarcinoma, in which it is diffusely spread through the cytoplasm.^[14]

Interactions

Role in cancer

The ability of chemotherapeutic drugs to access the cancer cells is inhibited by the heavy glycosylation in the extracellular domain of MUC1. The glycosylation creates a highly hydrophilic region which prevents hydrophobic chemotherapeutic drugs from passing through. This prevents the drugs from reaching their targets which usually reside within the cell. Similarly, the glycosylation has been shown to bind to growth factors. This allows cancer cells which produce a large amount of MUC1 to concentrate growth factors near their receptors, increasing receptor activity and the growth of cancer cells. MUC1 also prevents the interaction of immune cells with receptors on the cancer cell surface through steric hindrance. This inhibits an anti-tumor immune response.^[2]

Preventing cell death

MUC1 cytoplasmic tail has been shown to bind to p53. This interaction is increased by genotoxic stress. MUC1 and p53 were found to be associated with the p53 response element of the p21 gene promoter. This results in activation of p21 which results in cell cycle arrest. Association of MUC1 with p53 in cancer results in inhibition of p53-mediated apoptosis and promotion of p53-mediated cell cycle arrest.^[19]

Overexpression of MUC1 in fibroblasts increased the phosphorylation of Akt. Phosphorylation of Akt results in phosphorylation of Bcl-2-associated death promoter. This results in dissociation of Bcl-2-associated death promoter with Bcl-2 and Bcl-xL. Activation was shown to be dependent on the upstream activation of PI3K. Additionally, MUC1 was shown to increase expression of Bcl-xL. Overexpression of MUC1 in cancer. The presence of free Bcl-2 and Bcl-xL prevents the release of cytochrome c from mitochondria, thereby preventing apoptosis.^[20] MUC1 cytoplasmic tail is shuttled to the mitochondria through interaction with hsp90. This interaction is induced through phosphorylation of the MUC1 cytoplasmic tail by Src (gene). Src is activated by the EGF receptor family ligand Neuregulin. The cytoplasmic tail is then inserted into the mitochondrial outer membrane. Localization of MUC1 to the mitochondria prevents the activation of apoptotic mechanisms.^[21]

Promoting tumor invasion

MUC1 cytoplasmic tail was shown to interact with Beta-catenin. A SXXXXXSSL motif was identified in MUC1 that is conserved with other beta-catenin binding partners. This interaction was shown to be dependent on cell adhesion.^[22] Studies have demonstrated that MUC1 is phosphorylated on a YEKV motif. Phosphorylation of this site has been demonstrated by LYN through mediation of interleukin 7,^[23] Src through mediation of EGFR,^[24]^[25] and PRKCD.^[26] This interaction is antagonized by degradation of beta-catenin by GSK3B. MUC1 blocks the phosphorylation-dependent degradation of beta-catenin by GSK3B.^[27]^[28] The end result is that increased expression of MUC1 in cancer increases stabilized beta-catenin. This promotes the expression of vimentin and CDH2. These proteins are associated with a mesenchymal phenotype, characterized by increased motility and invasiveness. In cancer cells, increased expression of MUC1 promotes cancer cell invasion through beta-catenin, resulting in the initiation of epithelial-mesenchymal transition which promotes the formation of metastases.^[29]^[30]

Cancer Antigens (CA) 27.29 and 15-3

CA 27.29 (aka BR 27.29) and CA 15-3 measure different epitopes of the same protein antigen product of the MUC1 gene seen in breast cancer. CA 27.29 has enhanced sensitivity and specificity compared to CA 15-3 and is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer.

CA 27.29 levels over 100 U/mL and CA 15-3 levels over 25 U/mL are rare in benign conditions and suggest malignancy.

Diagnostic use in clinical pathology

Positive tumoral cells

Negative tumoral cells

As a therapeutic drug target

Using MUC1, vaccines are being tested against a type of blood cancer called multiple myeloma. The technology could in theory be applied to 90 percent of all known cancers, including prostate and breast cancer, solid and non-solid tumors. This method would activate the immune system by training T-cells to search out and destroy cells that display a specific molecule (or marker) of MUC1. MUC1 is found on nearly all epithelial cells, but it is over expressed in cancer cells, and its associated glycans are shorter than those of non-tumor-associated MUC1.^[31]

Because MUC1 is overexpressed (and differently glycosylated) in many cancers it has been investigated as a drug target, e.g. for the MUC1 vaccine ONT-10, which has had a phase 1 clinical study.^[32]

See also

References

1. ^{{cite journal | vauthors = Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D | title = Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin | journal = The Journal of Biological Chemistry | volume = 265 | issue = 25 | pages = 15286–93 | date = September 1990 | pmid = 1697589}}
2. ^¹{{cite journal |vauthors=Hollingsworth MA, Swanson BJ | title = Mucins in cancer: protection and control of the cell surface | journal = Nature Reviews Cancer | volume = 4 | issue = 1 | pages = 45–60 |date=January 2004 | pmid = 14681689 | doi = 10.1038/nrc1251 }}
3. ^{{cite journal |vauthors=Moncada DM, Kammanadiminiti SJ, Chadee K | title = Mucin and Toll-like receptors in host defense against intestinal parasites | journal = Trends Parasitol | volume = 19 | issue = 7 | pages = 305–311 |date=July 2003 | doi = 10.1016/S1471-4922(03)00122-3 | pmid = 12855381 }}
4. ^{{cite journal | vauthors = Gendler SJ | title = MUC1, the renaissance molecule | journal = J. Mammary Gland Biol Neoplasia | volume = 6 | issue = 3 | pages = 339–353 |date=July 2001 | pmid = 11547902 | doi = 10.1023/A:1011379725811}}
5. ^¹{{cite journal |vauthors=Brayman M, Thathiah A, Carson DD | title = MUC1: a multifunctional cell surface component of reproductive tissue epithelia | journal = Reprod Biol Endocrinol | volume = 2 | issue = | pages = 4 |date=January 2004 | pmid = 14711375 | doi = 10.1186/1477-7827-2-4 | pmc = 320498}}
6. ^{{cite journal | vauthors = Hattrup CL, Gendler SJ | title = Structure and function of the cell surface (tethered) mucins | journal = Annual Review of Physiology | volume = 70 | issue = | pages = 431–57 | date = 2008 | pmid = 17850209 | doi = 10.1146/annurev.physiol.70.113006.100659 }}
7. ^{{cite web | title = Entrez Gene: SEA Domain of MUC1| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4582| accessdate = }}
8. ^{{cite journal | vauthors = Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J | title = Cell-associated episialin is a complex containing two proteins derived from a common precursor | journal = The Journal of Biological Chemistry | volume = 267 | issue = 9 | pages = 6171–7 | date = March 1992 | pmid = 1556125}}
9. ^{{cite journal |vauthors=Julian J, Carson DD | title = Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells | journal = Biochem Biophys Res Commun | volume = 293 | issue = 4 | pages = 1183–1190 |date=May 2002 | pmid = 12054500 | doi = 10.1016/S0006-291X(02)00352-2}}
10. ^¹{{cite journal |vauthors=Singh PK, Hollingsworth MA | title = Cell surface-associated mucins in signal transduction | journal = Trends Cell Biol | volume = 16 | issue = 9 | pages = 467–476 |date=August 2006 | pmid = 16904320 | doi = 10.1016/j.tcb.2006.07.006}}
11. ^{{cite journal |vauthors=Lindén SK, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, Sutton P, McGuckin MA | title = MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy | journal = PLOS Pathog. | volume = 5 | issue = 10 | pages = e1000617 |date=October 2009 | pmid = 19816567 | pmc = 2752161 | doi = 10.1371/journal.ppat.1000617 }}
12. ^{{cite journal |vauthors=Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK | title = Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study | journal = J. Clin. Oncol. | volume = 21 | issue = 2 | pages = 211–22 |date=January 2003 | pmid = 12525512 | doi = 10.1200/JCO.2003.05.137 }}
13. ^{{cite journal|last1=Vlahopoulos|first1=SA|title= Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode|journal= Cancer Biology & Medicine|date=15 August 2017|pmid= 28884042|doi= 10.20892/j.issn.2095-3941.2017.0029|volume=14|issue=3|pages=254–270|pmc=5570602}}
14. ^{{cite book |author1=Cooper K |author2=Leong AS-Y |author3=Leong JW-M | title = Manual of diagnostic antibodies for immunohistology | publisher = Greenwich Medical Media | location = London | year = 2003 | pages = 205–206 | isbn = 978-1-84110-100-2 | oclc = | doi = | accessdate = }}
15. ^{{cite journal |vauthors=Li Y, Kufe D | title = The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn) | journal = Biochem. Biophys. Res. Commun. | volume = 281 | issue = 2 | pages = 440–3 |date=February 2001 | pmid = 11181067 | doi = 10.1006/bbrc.2001.4383 }}
16. ^¹{{cite journal |vauthors=Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D | title = Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein | journal = Mol. Cancer Res. | volume = 1 | issue = 10 | pages = 765–75 |date=August 2003 | pmid = 12939402 | doi = }}
17. ^¹{{cite journal |vauthors=Schroeder JA, Thompson MC, Gardner MM, Gendler SJ | title = Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland | journal = J. Biol. Chem. | volume = 276 | issue = 16 | pages = 13057–64 |date=April 2001 | pmid = 11278868 | doi = 10.1074/jbc.M011248200 }}
18. ^¹{{cite journal |vauthors=Pandey P, Kharbanda S, Kufe D | title = Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein | journal = Cancer Res | volume = 55 | issue = 18 | pages = 4000–4003 |date=September 1995 | pmid = 7664271}}
19. ^{{cite journal |vauthors=Wei X, Xu H, Kufe D | title = Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response | journal = Cancer Cell | volume = 7 | issue = 2 | pages = 167–178 |date=February 2005 | pmid = 15710329 | doi = 10.1016/j.ccr.2005.01.008}}
20. ^{{cite journal |vauthors=Raina D, Kharbanda S, Kufe D | title = The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts | journal = J Biol Chem | volume = 279 | issue = 20 | pages = 20607–20612 |date=May 2004 | pmid = 14999001 | doi = 10.1074/jbc.M310538200}}
21. ^{{cite journal |vauthors=Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D | title = MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90 | journal = Oncogene | volume = 25 | issue = 1 | pages = 20–31 |date=January 2006 | pmid = 16158055 | doi = 10.1038/sj.onc.1209012 }}
22. ^{{cite journal |vauthors=Yamamoto M, Bharti A, Li Y, Kufe D | title = Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion | journal = J. Biol. Chem. | volume = 272 | issue = 19 | pages = 12492–4 |date=May 1997 | pmid = 9139698 | doi = 10.1074/jbc.272.19.12492}}
23. ^{{cite journal |vauthors=Li Y, Chen W, Ren J, Yu WH, Li Q, Yoshida K, Kufe D | title = DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7 | journal = Cancer Biol. Ther. | volume = 2 | issue = 2 | pages = 187–93 | year = 2003 | pmid = 12750561 | doi = 10.4161/cbt.2.2.282}}
24. ^{{cite journal |vauthors=Li Y, Kuwahara H, Ren J, Wen G, Kufe D | title = The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin | journal = J. Biol. Chem. | volume = 276 | issue = 9 | pages = 6061–4 |date=March 2001 | pmid = 11152665 | doi = 10.1074/jbc.C000754200 }}
25. ^{{cite journal |vauthors=Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, Carraway KL, Kufe D | title = The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin | journal = J. Biol. Chem. | volume = 276 | issue = 38 | pages = 35239–42 |date=September 2001 | pmid = 11483589 | doi = 10.1074/jbc.C100359200 }}
26. ^{{cite journal |vauthors=Ren J, Li Y, Kufe D | title = Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling | journal = J. Biol. Chem. | volume = 277 | issue = 20 | pages = 17616–22 |date=May 2002 | pmid = 11877440 | doi = 10.1074/jbc.M200436200 }}
27. ^{{cite journal |vauthors=Li Y, Bharti A, Chen D, Gong J, Kufe D | title = Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin | journal = Mol. Cell. Biol. | volume = 18 | issue = 12 | pages = 7216–24 |date=December 1998 | pmid = 9819408 | pmc = 109303 | doi = 10.1128/mcb.18.12.7216}}
28. ^{{cite journal |vauthors=Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D | title = MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin | journal = Cancer Res | volume = 65 | issue = 22 | pages = 10413–10422 |date=November 2005 | pmid = 16288032 | doi = 10.1158/0008-5472.CAN-05-2474}}
29. ^{{cite journal |vauthors=Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ | title = MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion | journal = Oncogene | volume = 22 | issue = 9 | pages = 1324–32 |date=March 2003 | pmid = 12618757 | doi = 10.1038/sj.onc.1206291 }}
30. ^{{cite journal |vauthors=Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, Gendler SJ, Mukherjee P | title = MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition | journal = Oncogene | volume = 30 | issue = 12 | pages = 1449–1459 |date=March 2011 | pmid = 21102519 | doi = 10.1038/onc.2010.526 | pmc = 3063863}}
31. ^{{cite journal |vauthors=Gaidzik N, Westerlind U, Kunz H | title = The development of synthetic antitumour vaccines from mucin glycopeptide antigens | journal = Chem Soc Rev | volume = 42 | issue = 10 | pages = 4421–42 |date=May 2013 | pmid = 23440054 | doi = 10.1039/c3cs35470a }}
32. ^{{cite journal|vauthors = Nemunaitis J, Bedell C, Klucher K, Vo A, Whiting S|title = Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer|journal=Journal for ImmunoTherapy of Cancer|volume = 1|issue = Suppl 1|year = 2013|pages = P240|issn = 2051-1426|doi = 10.1186/2051-1426-1-S1-P240|pmc = 3990302}}